GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Trump Signs Order to Cut Routine Childhood Vaccines 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
3 clinical-grade skincare creams you really shouldn’t buy online 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Add as a preferred source on Google
Moderna (NASDAQ: MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its mRNA-based influenza vaccine, mFLUSIVA, for adults aged 50 and older. The approval marks a significant milestone for the biotechnology company, making mFLUSIVA its first approved mRNA flu vaccine and its fourth FDA-approved product in the United States. Globally, the vaccine becomes Moderna's fifth approved product.
The company plans to begin shipping mFLUSIVA to select retailers across the United States in the coming weeks, allowing availability ahead of the 2026–2027 respiratory virus season.
The FDA's decision follows a unanimous recommendation from the Vaccines and Related Biological Products Advisory Committee and is supported by results from a Phase 3 clinical trial involving 40,805 adults aged 50 years and older across 11 countries. The study demonstrated the vaccine's effectiveness while maintaining an acceptable safety profile, with researchers reporting no new safety concerns.
For adults aged 65 and above, the vaccine received accelerated approval based on immune response data from a separate U.S. trial that enrolled 2,992 participants. Moderna said it will conduct post-marketing confirmatory studies to further verify the vaccine's clinical benefits for this older age group, as required under the accelerated approval pathway.
Moderna CEO Stephane Bancel said the company's mRNA technology expands vaccination options for older adults, who face a higher risk of severe influenza and related complications. The company believes its mRNA platform can help improve protection against seasonal flu while supporting broader innovation in vaccine development.
Beyond the U.S., Moderna is seeking to expand the vaccine's global reach. Regulatory applications for mFLUSIVA are currently under review in the European Union, Canada, and Australia, with additional submissions planned later this year. If approved in these markets, the vaccine could strengthen Moderna's growing respiratory vaccine portfolio and reinforce its position in the global influenza vaccine market.
